Harvard Bioscience (HBIO) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts HBIO Hot Sheet
Price: $8.38 +1.82%
Revenue Growth %: +6.1%
Financial Fact:
General and administrative expenses: 4.8M
Today's EPS Names:
SICP, OMID, ELME, More
Revenue Growth %: +6.1%
Financial Fact:
General and administrative expenses: 4.8M
Today's EPS Names:
SICP, OMID, ELME, More
Join SI Premium – FREE
Harvard Bioscience (NASDAQ: HBIO) reported Q1 EPS of ($0.01), in-line with the analyst estimate of ($0.01). Revenue for the quarter came in at $21.77 million versus the consensus estimate of $20 million.
For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Can JetBlue still avoid bankruptcy? Analysis says yes, but it won’t be easy
- Cadence Design Systems (CDNS) Tops Q3 EPS by 7c; offers guidance
- Intel to Buy Israeli Startup Classiq
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
